株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のジェネリック抗癌剤市場の見通し

Global Cancer Generics Market Forecast to 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 310599
出版日 ページ情報 英文 110 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.05円で換算しております。
Back to Top
世界のジェネリック抗癌剤市場の見通し Global Cancer Generics Market Forecast to 2022
出版日: 2016年10月10日 ページ情報: 英文 110 Pages
概要

当レポートでは、世界のジェネリック抗癌剤市場について調査分析し、市場の現状と見通し、セグメント別の医薬品動向、主要企業プロファイルなどを含めて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 世界の癌治療薬市場の見通し

  • 癌の発症率
  • 抗癌剤市場

第4章 市場の成長因子と課題

  • 成長因子
  • 課題
  • 機会

第5章 世界のジェネリック抗癌剤市場の分析

第6章 世界のジェネリック抗癌剤市場:投与経路別

  • 経口ジェネリック医薬品
    • Arimidex (Anastrozole)
    • Femara (Letrozole)
    • Hycamtin (Topotecan)
    • Stivarga (Regorafenib)
    • Tarceva (Erlotinib)
    • Xalkori (Crizotinib)
    • Xeloda (Capecitabine)
    • Gleevec/Glivec (Imatinib Mesylate)
    • Nolvadex (Tamoxifen Citrate)
    • Targretin (Bexarotene)
  • 注入ジェネリック医薬品
    • Camptosar (Irinotecan Hydrochloride)
    • Eloxatin (Oxaliplatin)
    • Gemzar (Gemcitabine Hydrochloride)
    • Navelbine (Vinorelbine Tartrate)
    • Platinol (Cisplatin)
    • Taxol (Paclitaxel)
    • Taxotere (Docetaxel)
    • Fusilev (Levoleucovorin)
    • Ellence (Epirubicin Hydrochloride)
    • Adriamycin (Doxorubicin Hydrochloride)

第7章 世界のジェネリック抗癌剤市場:主な適応症別

  • 肺癌
  • 乳癌
  • 大腸癌
  • 胃癌
  • 前立腺癌

第9章 動向と発展

第10章 M&A

第11章 主要企業

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.

As per RNCOS report "Global Cancer Generics Market Forecast to 2022", the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.

The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.

Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.

Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.

The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Cancer Drugs Market Outlook 2022

  • 3.1 Cancer Incidences
  • 3.2 Cancer Drug Market

4. Market Drivers & Challenges

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Strategic Collaborations
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 Ability to Curb Healthcare Cost
  • 4.2 Challenges
    • 4.2.1 Growing Backlog of Generic Drug Applications
    • 4.2.2 Counterfeit Generic Drugs
  • 4.3 Opportunities
    • 4.3.1 Patent Expiry of Blockbuster Oncology Drugs
    • 4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries

5. Global Cancer Generics Market Analysis 2022

6. Global Cancer Generics Market by Mode of Administration

  • 6.1 Oral Generics
    • 6.1.1 Arimidex (Anastrozole)
    • 6.1.2 Femara (Letrozole)
    • 6.1.3 Hycamtin (Topotecan)
    • 6.1.4 Stivarga (Regorafenib)
    • 6.1.5 Tarceva (Erlotinib)
    • 6.1.6 Xalkori (Crizotinib)
    • 6.1.7 Xeloda (Capecitabine)
    • 6.1.8 Gleevec/Glivec (Imatinib Mesylate)
    • 6.1.9 Nolvadex (Tamoxifen Citrate)
    • 6.1.10 Targretin (Bexarotene)
    • 6.2 Injectables Generics
    • 6.2.1 Camptosar (Irinotecan Hydrochloride)
    • 6.2.2 Eloxatin (Oxaliplatin)
    • 6.2.3 Gemzar (Gemcitabine Hydrochloride)
    • 6.2.4 Navelbine (Vinorelbine Tartrate)
    • 6.2.5 Platinol (Cisplatin)
    • 6.2.6 Taxol (Paclitaxel)
    • 6.2.7 Taxotere (Docetaxel)
    • 6.2.8 Fusilev (Levoleucovorin)
    • 6.2.9 Ellence (Epirubicin Hydrochloride)
    • 6.2.10 Adriamycin (Doxorubicin Hydrochloride)

7. Global Cancer Generics Market by Major Indications

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Stomach Cancer
  • 7.5 Prostate Cancer

8. Global Cancer Generics Market by Geographic Regions

  • 8.1 US
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Generic Version of Blockbuster Cancer Drug
  • 9.2 Entry of Indian Generic Cancer Drug in US

10. Mergers & Acquisitions

11. Key Players

  • 11.1 Fresenius Kabi AG
  • 11.2 Pfizer Inc
  • 11.3 Teva Pharmaceutical Industries Ltd
  • 11.4 Mylan N.V
  • 11.5 Sun Pharmaceutical Industries Ltd
  • 11.6 Sandoz International GmbH - A Novartis Company
  • 11.7 Sanofi
  • 11.8 Dr. Reddy's Laboratories Ltd
  • 11.9 Cipla Ltd
  • 11.10 Apotex Inc

List of Figures:

  • Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
  • Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
  • Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
  • Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
  • Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
  • Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-3: Global -Lung Cancer Incidences (Million), 2015 & 2025
  • Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-5: Global -Breast Cancer Incidences (Million), 2015 & 2025
  • Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-7: Global -Colorectal Cancer Incidences (Million), 2015 & 2025
  • Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-9: Global -Stomach Cancer Incidences (Million), 2015 & 2025
  • Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-11: Global -Prostate Cancer Incidences (Million), 2015 & 2025
  • Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
  • Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
  • Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
  • Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025
  • Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
  • Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
  • Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
  • Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
  • Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
  • Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
  • Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
  • Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
  • Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
  • Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
  • Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
  • Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
  • Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
  • Figure 11-14: Dr. Reddy's Laboratories - Revenue by Business Segment (%), FY 2016
  • Figure 11-15: Dr. Reddy's Laboratories - Revenue by Geographic Region (%), FY 2016
  • Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016

List of Tables:

  • Table 3-1: Most Prevalent Types of Cancer, 2015
  • Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
  • Table 6-1: List of Companies Dealing in Generic Arimidex
  • Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
  • Table 6-3: List of Companies Dealing in Generic Femara
  • Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
  • Table 6-5: List of Companies Dealing in Generic Hycamtin
  • Table 6-6: List of Companies Dealing in Generic Xeloda
  • Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
  • Table 6-8: List of Companies Dealing in Generic Gleevec
  • Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
  • Table 6-10: List of Companies Dealing in Generic Nolvadex
  • Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
  • Table 6-12: List of Companies Dealing in Generic Targretin
  • Table 6-13: List of Companies Dealing in Generic Camptosar
  • Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
  • Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
  • Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
  • Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
  • Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
  • Table 6-19: List of Companies Dealing in Generic Platinol (Cisplatin)
  • Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
  • Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
  • Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
  • Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
  • Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
  • Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride)
  • Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride)
  • Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
  • Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
  • Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
  • Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
  • Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
  • Table 10-1: Global - Major M&A in the Generics Industry (2014-2016)
  • Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs
  • Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-4: Pfizer Inc - Key Cancer Generic Products
  • Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs
  • Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-8: Mylan N.V. - Key Cancer Generic Drugs
  • Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs
  • Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs
  • Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-14: Sanofi - Key Cancer Generic Drugs
  • Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs
  • Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs
  • Table 11-19: Apotex Inc. - Key Cancer Generic Drugs
Back to Top